Autologous CD6-CAR Tregs for stage-3 T1D
What this study tests
City of Hope pilot study testing whether autologous anti-CD6 chimeric antigen receptor regulatory T cells can be manufactured and safely infused in adults with stage-3 type 1 diabetes.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-13.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults 18-35 with stage-3 T1D. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- Not yet started. Live registry check on 27 August 2026 confirms the study is still not yet recruiting; estimated start September 2026, with 6 participants planned.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Toxicity including CRS, ICANS, hyperglycemia and DKA
- Feasibility of investigational product manufacture
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT07395050: Autologous CD6-CAR Tregs for stage-3 T1D · Trial registry